http://www.gsk.com/media/646542/q1-2015-results-announcement.pdf
葛蘭素公佈的財報新聞稿(如上連結),在第13,14頁有揭露這筆收入,
****
Acquisition accounting and other adjustments resulted in a net credit of £8,615 million (Q1 2014: charge of£59 million). This included the profit on disposal of the Oncology business to Novartis of £9,262 million, partlyoffset by a further increase in the liability for the contingent consideration for the acquisition of the formerShionogi-ViiV Healthcare joint venture of £706 million following the continuation of the improved salesperformances of Tivicay and Triumeq
****